Skip to main content

RT @doctorRBC: First Head-to-Head bDMARD study in axSpA to assess radiographic progression - secukinumab vs. adalimumab

Mar 19, 2023 12:55 pm
Social Author Name
Robert B Chao, MD
Tweet Content
First Head-to-Head bDMARD study in axSpA to assess radiographic progression - secukinumab vs. adalimumab biosimilar - 66% of either arm prevented radiographic progression - no difference between two arms but good news is radiographic progression is low! @RheumNow #RNL2023 https://t.co/xq8GhN7kzr
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×